The assessment of human organic cation transporter 1 (hOCT1)
mRNA expression in patients with chronic myelogenous leukemia
is affected by the proportion of different cells types in the
analyzed cell population

J 2010

The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population

RÁČIL, Zdeněk; Filip RÁZGA; Lucie BUREŠOVÁ; Tomáš JURČEK; Dana DVOŘÁKOVÁ et al.

Základní údaje

Originální název

The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population

Autoři

RÁČIL, Zdeněk; Filip RÁZGA; Lucie BUREŠOVÁ; Tomáš JURČEK; Dana DVOŘÁKOVÁ; Daniela ŽÁČKOVÁ; Shira TIMILSINA; Petr CETKOVSKÝ a Jiří MAYER

Vydání

American Journal of Hematology, 2010, 0361-8609

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.576

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/10:00067349

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1002/ajh.21722

UT WoS

000279506200018

Klíčová slova anglicky

RESIDUAL DISEASE DETECTION; POLYMERASE-CHAIN-REACTION; CHRONIC MYELOID-LEUKEMIA; CANCER PROGRAM; OCT-1 ACTIVITY; IMATINIB; RESISTANCE; DETERMINANT; EUROPE

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 29. 4. 2014 09:18, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

The monitoring of hOCT1 mRNA expression in patients with chronic myelogenous leukemia (CML) was used for predicting the response to imatinib treatment. However, different cell populations from patients who received various degrees of pretreatment were used for this analysis. Therefore, several biases in the results and their interpretation may arise. We investigated hOCT1 mRNA expression in different cell populations of peripheral blood (PB) from healthy volunteers and in imatinib nave de novo CML patients by analyzing changes in hOCT1 mRNA expression during the first 6 months of imatinib therapy. The hOCT1 mRNA expression was significantly higher in PB polymorphonuclears compared to mononuclears. The hOCT1 mRNA expression in total PB leukocytes is, therefore, preferentially determined by the percentage of polymorphonuclears. Expression in each analyzed group of cells was always significantly lower in imatinib nave de novo CML patients compared to healthy volunteers. This difference disappeared after the initiation of imatinib therapy, suggesting that CML tumor burden and the degree of pretreatment at the time of monitoring were both influencing factors.

Návaznosti

MSM0021622430, záměr

Název: Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie

Citovat

RÁČIL, Zdeněk; Filip RÁZGA; Lucie BUREŠOVÁ; Tomáš JURČEK; Dana DVOŘÁKOVÁ; Daniela ŽÁČKOVÁ; Shira TIMILSINA; Petr CETKOVSKÝ a Jiří MAYER. The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population. American Journal of Hematology. 2010, roč. 85, č. 7, s. 525-528. ISSN 0361-8609. Dostupné z: https://doi.org/10.1002/ajh.21722.

@article{966872,
   author = {Ráčil, Zdeněk and Rázga, Filip and Burešová, Lucie and Jurček, Tomáš and Dvořáková, Dana and Žáčková, Daniela and Timilsina, Shira and Cetkovský, Petr and Mayer, Jiří},
   article_number = {7},
   doi = {https://doi.org/10.1002/ajh.21722},
   keywords = {RESIDUAL DISEASE DETECTION; POLYMERASE-CHAIN-REACTION; CHRONIC MYELOID-LEUKEMIA; CANCER PROGRAM; OCT-1 ACTIVITY; IMATINIB; RESISTANCE; DETERMINANT; EUROPE},
   language = {eng},
   issn = {0361-8609},
   journal = {American Journal of Hematology},
   title = {The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population},
   volume = {85},
   year = {2010}
}

TY  - JOUR
ID  - 966872
AU  - Ráčil, Zdeněk - Rázga, Filip - Burešová, Lucie - Jurček, Tomáš - Dvořáková, Dana - Žáčková, Daniela - Timilsina, Shira - Cetkovský, Petr - Mayer, Jiří
PY  - 2010
TI  - The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population
JF  - American Journal of Hematology
VL  - 85
IS  - 7
SP  - 525-528
EP  - 525-528
SN  - 03618609
KW  - RESIDUAL DISEASE DETECTION
KW  - POLYMERASE-CHAIN-REACTION
KW  - CHRONIC MYELOID-LEUKEMIA
KW  - CANCER PROGRAM
KW  - OCT-1 ACTIVITY
KW  - IMATINIB
KW  - RESISTANCE
KW  - DETERMINANT
KW  - EUROPE
N2  - The monitoring of hOCT1 mRNA expression in patients with chronic myelogenous leukemia (CML) was used for predicting the response to imatinib treatment. However, different cell populations from patients who received various degrees of pretreatment were used for this analysis. Therefore, several biases in the results and their interpretation may arise. We investigated hOCT1 mRNA expression in different cell populations of peripheral blood (PB) from healthy volunteers and in imatinib nave de novo CML patients by analyzing changes in hOCT1 mRNA expression during the first 6 months of imatinib therapy. The hOCT1 mRNA expression was significantly higher in PB polymorphonuclears compared to mononuclears. The hOCT1 mRNA expression in total PB leukocytes is, therefore, preferentially determined by the percentage of polymorphonuclears. Expression in each analyzed group of cells was always significantly lower in imatinib nave de novo CML patients compared to healthy volunteers. This difference disappeared after the initiation of imatinib therapy, suggesting that CML tumor burden and the degree of pretreatment at the time of monitoring were both influencing factors.
ER  -

RÁČIL, Zdeněk; Filip RÁZGA; Lucie BUREŠOVÁ; Tomáš JURČEK; Dana DVOŘÁKOVÁ; Daniela ŽÁČKOVÁ; Shira TIMILSINA; Petr CETKOVSKÝ a Jiří MAYER. The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population. \textit{American Journal of Hematology}. 2010, roč.~85, č.~7, s.~525-528. ISSN~0361-8609. Dostupné z: https://doi.org/10.1002/ajh.21722.

Přehled o publikaci